What's New
AFTD and ADDF Award $2.5 million to Vesper Biotechnology for Drug VES001 Clinical Trial in FTD
The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) recently awarded $2.5 million as part of their shared funding opportunity called the Treat FTD Fund to Danish biotechnology…
AFTD Ambassador and “Protective Mama Bear” Dawn Kirby Interviewed on Podcast
Dawn Kirby’s daughter Kara was diagnosed with FTD at age 29. In a recent episode of the podcast For Their Thoughts, she shared her experience as a mother fighting for…
FTD Science Digest – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for…
Meet the Researcher: Indira García-Cordero, PhD
“Over the years, I have had the privilege of meeting and working with people living with FTD and their families. Their strength and resilience have inspired me and motivated me…
FTD Research Spotlight – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for…
New Recommendation: Expanding Genetic Counseling and Testing for People Diagnosed with FTD
The FTD genetic research landscape is evolving at an unprecedented pace. Although most FTD cases do not have a hereditary component, numerous clinical trials are now targeting gene-specific treatments, areas…
A Rose with Pink Petals: How FTD Revealed Deb Jobe’s Hidden Artist
Deb Jobe, co-chair of the AFTD Persons with FTD Advisory Council, was featured in the journal Brain & Life for the blooming of her artistic ability alongside FTD symptoms. Jobe…
When “I’m Fine” Isn’t Fine – Understanding Anosognosia in FTD
“I’m not going back to that doctor. I don’t have FTD. I’m fine.” This type of response from someone who has just received an FTD diagnosis can seem like denial,…
Pave the Path Forward to End FTD with a Year-End Gift
Since AFTD was founded in 2002 by Helen-Ann Comstock with her personal gift of $1,000, our work has been powered by the dedication of volunteers, donors, and all those we…
Alector Therapeutics Announces Results From Their Phase 3 Clinical Trial Evaluating Latozinemab
On October 21, 2025, Alector Therapeutics announced results from their Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) for people with FTD caused by variants in the progranulin (GRN gene).…
